Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response rates of up to 90% in patients treated with Ibtrozi for locally advanced or ...

Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer Approval follows ...